Although Phor21 lytic peptide is more effective at killing cancer cells (with a high negative membrane charge) than non-tumour cells, the peptide efficacy can be improved by conjugating it to ligands of the cell surface receptors that are known to be overexpressed in cancer cells [46,48]. The gene discussed is CD177; the disease is cancer.